Phase I
The fifth annual CAR-TCR Summit will kick off in Boston Tuesday with a focus on advancements in immunotherapies targeting various cancers, as well as challenges that face the field.
Amgen shares dropped 4.2% in pre-market trading at good but not amazing results in an early-stage trial of AMG 510 in in patients with previously treated KRAS G12C-mutated solid tumors.
When Eli Lilly and Company acquired Loxo Oncology for $8 billion, the company was gambling on several pipeline drugs in oncology.
Ultragenyx Pharmaceutical Inc. announced positive data from the second dose cohort of the ongoing Phase 1/2 study of DTX401, an adeno-associated virus based gene therapy for the treatment of glycogen storage disease type Ia.
Hutchison China MediTech Limited has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta isoform inhibitor, in patients with relapsed or refractory lymphoma.
Akari Therapeutics, Plc announced financial results for the second quarter ended June 30, 2019 and recent clinical progress.
Company’s insulin-based Imotope™ IMCY-0098 shows excellent safety profile and promising clinical trends while eliciting immune responses supporting the proposed mode of action
Successful validation of standardized clinical procedure for instillation of nanoparticles in first patient cohort
This study aimed to determine the appropriate dose for Japanese patients treated with lurbinectedin, in monotherapy, for advanced solid tumors.
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
PRESS RELEASES